secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000899923-23-000102
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics prices upsized 6.47M-share offering at $17.00 for ~$110M gross
------------------------------------------------------------------------------

- Offering of 6,470,588 shares upsized; priced at $17.00/share; expected gross proceeds ~$110M.
- Underwriters granted 30-day option for up to 970,588 additional shares at same price.
- Net proceeds: ~$40M to repay asset-based revolving credit facility; ~$57.5M to settle securities class action (In re Myriad Genetics).
- Remainder for working capital and general corporate purposes; closing expected Nov 13, 2023.
- Goldman Sachs, Morgan Stanley, and Wells Fargo acting as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000102/0000899923-23-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000102/mygn-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer